ホーム>>Signaling Pathways>> PI3K/Akt/mTOR Signaling>> mTOR>>GSK1059615

GSK1059615

カタログ番号GC11018

GSK1059615 は、PI3Kα/β/δ/γ (可逆) および mTOR の二重阻害剤であり、IC50 はそれぞれ 0.4 nM/0.6 nM/2 nM/5 nM および 12 nM です。

Products are for research use only. Not for human use. We do not sell to patients.

GSK1059615 化学構造

Cas No.: 958852-01-2

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$69.00
在庫あり
5mg
$63.00
在庫あり
10mg
$104.00
在庫あり
50mg
$405.00
在庫あり
100mg
$585.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

GSK1059615 is inhibitor of pan-PI3K with IC50 values of 0.4nM, 0.6nM, 5nM, 2nM and 12nM for PI3Kα, P13Kβ, P13Kγ, P13Kδ and mTOR, respectively [1].

GSK1059615 is a potent and reversible inhibitor of P13K. It also has inhibition efficacy to the oncogenic mutants of PI3Kα. The thiazolidinedione ring of GSK1059615 forms an interaction with the catalytic lysine (Lys833) within the ATP-binding pocket. In cellular assay, GSK1059615 is reported to induce G1 arrest and apoptosis in a variety of cell lines. Among these, the breast tumor cells display more sensitive. Moreover, GSK1059615 significantly suppresses tumor growth and increases plasma insulin levels in xenograft mice [1, 2].

References:
[1] Carnero A. Novel inhibitors of the PI3K family. 2009.
[2] Knight S D, Adams N D, Burgess J L, et al. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Medicinal Chemistry Letters, 2010, 1(1): 39-43.

レビュー

Review for GSK1059615

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GSK1059615

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.